What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed?

During the EHA2021 Virtual Congress, the MDS Hub spoke with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What hematologic toxicities occur after venetoclax + azacitidine in MDS and how can they be managed? 

In this podcast, Platzbecker discusses the potential hematologic toxicities associated with the combination of venetoclax and azacitidine, and how to manage these toxicities in patients with high-risk MDS. He highlights the key points of a study presented during EHA2021, including dose modification considerations, overall response rates, infectious complications, and other side effects. Finally, Platzbecker believes this toxicity analysis provides clinically valuable information to doctors and hematologists who are already treating patients with this combination.